Should I buy or sell CorMedix stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRMD shares. View CRMD analyst ratings or view top-rated stocks .

What is CorMedix's stock price target for 2024?

4 analysts have issued 1-year target prices for CorMedix's shares. Their CRMD share price targets range from $9.00 to $19.00. On average, they expect the company's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 141.6% from the stock's current price. View analysts price targets for CRMD or view top-rated stocks among Wall Street analysts .

How have CRMD shares performed in 2024?

CorMedix's stock was trading at $3.76 on January 1st, 2024. Since then, CRMD shares have increased by 43.1% and is now trading at $5.38. View the best growth stocks for 2024 here .

Are investors shorting CorMedix?

CorMedix saw a increase in short interest in March. As of March 31st, there was short interest totaling 8,250,000 shares, an increase of 6.2% from the March 15th total of 7,770,000 shares. Based on an average trading volume of 443,800 shares, the short-interest ratio is presently 18.6 days. View CorMedix's Short Interest .

When is CorMedix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CRMD earnings forecast .

How were CorMedix's earnings last quarter?

CorMedix Inc. (NASDAQ:CRMD) announced its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.05.

What ETFs hold CorMedix's stock?

ETFs with the largest weight of CorMedix (NASDAQ:CRMD) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) . Amplify Treatments, Testing and Advancements ETF (GERM) .

When did CorMedix's stock split?

CorMedix's stock reverse split on the morning of Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of CorMedix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Amarin (AMRN) , NVIDIA (NVDA) , AcelRx Pharmaceuticals (ACRX) , Gigamon (GIMO) , Conatus Pharmaceuticals (CNAT) , Nabriva Therapeutics (NBRV) , QUALCOMM (QCOM) , AVEO Pharmaceuticals (AVEO) , Boeing (BA) and Marvell Technology (MRVL) .

Who are CorMedix's major shareholders?

CorMedix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include GSG Advisors LLC (0.07%). Insiders that own company stock include Elizabeth Masson-Hurlburt, Joseph Todisco, Matthew T David and Myron Kaplan. View institutional ownership trends .

How do I buy shares of CorMedix?

Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CRMD

CorMedix (CRMD) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free CRMD Stock Alerts

$5.38

-0.46 (-7.88%)

(As of 04/15/2024 ET)

Compare

Today's Range: $5.16
▼
$6.17
50-Day Range: $2.94
▼
$6.39
52-Week Range: $2.57
▼
$7.00

Volume: 1.50 million shs
Average Volume: 526,838 shs
Market Capitalization: $294.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.00

Get CorMedix alerts:

CorMedix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 141.6% Upside
$13.00 Price Target
Short Interest: Bearish
15.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.35
Based on 14 Articles This Week
Insider Trading: Acquiring Shares
$50,718 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.83) to ($0.31) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.42 out of 5 stars

Medical Sector

748th out of 929 stocks

Pharmaceutical Preparations Industry

345th out of 428 stocks

3.5

Analyst's Opinion

Consensus Rating
CorMedix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
CorMedix has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
15.05% of the outstanding shares of CorMedix have been sold short.
Short Interest Ratio / Days to Cover
CorMedix has a short interest ratio ("days to cover") of 18.6, which indicates bearish sentiment.
Change versus previous month
Short interest in CorMedix has recently increased by 6.18%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
CorMedix does not currently pay a dividend.
Dividend Growth
CorMedix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CRMD.

3.0

News and Social Media Coverage

News Sentiment
CorMedix has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for CorMedix this week, compared to 2 articles on an average week.
Search Interest
7 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.
MarketBeat Follows
9 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CorMedix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,718.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.60% of the stock of CorMedix is held by insiders.
Percentage Held by Institutions
Only 34.18% of the stock of CorMedix is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for CorMedix are expected to grow in the coming year, from ($0.83) to ($0.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CorMedix is -5.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CorMedix is -5.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CorMedix has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About CorMedix Stock (NASDAQ:CRMD)

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CRMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRMD Stock News Headlines

March 15, 2024 | insidertrades.com

CorMedix Inc. (NASDAQ:CRMD) CEO Joseph Todisco Purchases 13,561 Shares

April 15, 2024 | investorplace.com

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

April 15, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 15, 2024 | globenewswire.com

CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)

April 15, 2024 | finance.yahoo.com

CRMD Apr 2024 7.000 call

April 15, 2024 | finance.yahoo.com

CRMD Apr 2024 8.000 put

April 11, 2024 | finance.yahoo.com

CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference

April 11, 2024 | globenewswire.com

CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference

April 15, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 10, 2024 | americanbankingnews.com

CorMedix (NASDAQ:CRMD) Receives "Market Outperform" Rating from JMP Securities

April 10, 2024 | americanbankingnews.com

CorMedix (NASDAQ:CRMD) Receives "Buy" Rating from Needham & Company LLC

April 9, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)

April 8, 2024 | globenewswire.com

CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC

April 2, 2024 | finance.yahoo.com

Breakeven On The Horizon For CorMedix Inc. (NASDAQ:CRMD)

March 27, 2024 | finance.yahoo.com

CorMedix Inc. to Present at the Needham Annual Healthcare Conference

March 16, 2024 | finance.yahoo.com

CRMD Apr 2024 6.000 put

March 16, 2024 | finance.yahoo.com

CRMD Apr 2024 3.000 put

March 16, 2024 | finance.yahoo.com

CRMD Apr 2024 3.000 call

March 13, 2024 | markets.businessinsider.com

Truist Financial Reaffirms Their Buy Rating on Cormedix (CRMD)

March 13, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cencora (COR), Cormedix (CRMD) and NeueHealth Inc (NEUE)

March 13, 2024 | finance.yahoo.com

CorMedix Inc. (NASDAQ:CRMD) Q4 2023 Earnings Call Transcript

March 13, 2024 | seekingalpha.com

Ayr Wellness reports mixed Q4 results; initiates Q1 FY24 outlook

March 12, 2024 | markets.businessinsider.com

Buy Rating on Cormedix Amidst DefenCath Launch and Strong Financial Positioning

March 12, 2024 | marketwatch.com

CorMedix Shares Move Lower After 4Q Update

March 12, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Cormedix (CRMD), PROCEPT BioRobotics (PRCT)

March 12, 2024 | msn.com

CorMedix (CRMD) Q4 2023 Earnings Call Transcript

March 12, 2024 | finance.yahoo.com

Cormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities for DefenCath

See More Headlines

Receive CRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CRMD
CUSIP: N/A
CIK: 1410098
Web: www.cormedix.com
Phone: (908) 517-9500
Fax: 908-429-4307
Employees: 82
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.00
High Stock Price Target: $19.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +143.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-46,340,000.00
Net Margins: N/A
Pretax Margin: -132,646.69%
Return on Equity: -72.31%
Return on Assets: -63.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.97
Quick Ratio: 6.78

Sales & Book Value

Annual Sales: $60,000.00
Price / Sales: 4,868.96
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.28 per share
Price / Book: 4.16

Miscellaneous

Outstanding Shares: 54,810,000
Free Float: 52,291,000
Market Cap: $292.14 million
Optionable: Optionable
Beta: 1.86

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Joseph Todisco MBA (Age 47)
CEO & Director
Comp: $1.07M
Dr. Matthew T. David M.D. (Age 45)
Executive VP & CFO
Comp: $597.27k
Ms. Erin Mistry (Age 41)
Executive VP & Chief Commercial Officer
Comp: $561.57k
Ms. Elizabeth Masson-Hurlburt B.A. (Age 44)
Executive VP and Chief Clinical Strategy & Operations Officer
Comp: $538.91k
Ms. Kaufman Beth Zelnick Esq.
Executive VP, Chief Legal Officer & Corporate Secretary
Donna Ucci
Senior VP & Head of Global Quality
Dr. Tushar Mukherjee
Senior VP & Head of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRMD Stock Analysis - Frequently Asked Questions

Should I buy or sell CorMedix stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRMD shares.
View CRMD analyst ratings or view top-rated stocks.
What is CorMedix's stock price target for 2024?: 4 analysts have issued 1-year target prices for CorMedix's shares. Their CRMD share price targets range from $9.00 to $19.00. On average, they expect the company's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 141.6% from the stock's current price.
View analysts price targets for CRMD or view top-rated stocks among Wall Street analysts.
How have CRMD shares performed in 2024?: CorMedix's stock was trading at $3.76 on January 1st, 2024. Since then, CRMD shares have increased by 43.1% and is now trading at $5.38.
View the best growth stocks for 2024 here.
Are investors shorting CorMedix?: CorMedix saw a increase in short interest in March. As of March 31st, there was short interest totaling 8,250,000 shares, an increase of 6.2% from the March 15th total of 7,770,000 shares. Based on an average trading volume of 443,800 shares, the short-interest ratio is presently 18.6 days.
View CorMedix's Short Interest.
When is CorMedix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CRMD earnings forecast.
How were CorMedix's earnings last quarter?: CorMedix Inc. (NASDAQ:CRMD) announced its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.05.

What ETFs hold CorMedix's stock?: ETFs with the largest weight of CorMedix (NASDAQ:CRMD) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).Amplify Treatments, Testing and Advancements ETF (GERM).
When did CorMedix's stock split?: CorMedix's stock reverse split on the morning of Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.
What other stocks do shareholders of CorMedix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Amarin (AMRN), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gigamon (GIMO), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV), QUALCOMM (QCOM), AVEO Pharmaceuticals (AVEO), Boeing (BA) and Marvell Technology (MRVL).
Who are CorMedix's major shareholders?: CorMedix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include GSG Advisors LLC (0.07%). Insiders that own company stock include Elizabeth Masson-Hurlburt, Joseph Todisco, Matthew T David and Myron Kaplan.
View institutional ownership trends.
How do I buy shares of CorMedix?: Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRMD) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CorMedix (CRMD) Stock Price, News & Analysis

CorMedix MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About CorMedix Stock (NASDAQ:CRMD)

CRMD Stock Price History

CRMD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CRMD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™